menu
    • menu
    [{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Iron Sucrose","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Renibus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Renibus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Renibus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Emcure Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Iron Sucrose","moa":"Phosphate","graph1":"Nephrology","graph2":"Approved","graph3":"Emcure Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Chewable Tablet","sponsorNew":"Emcure Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emcure Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Iron Sucrose","moa":"Phosphate","graph1":"Nephrology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Chewable Tablet","sponsorNew":"CSL Vifor \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor \/ Not Applicable"},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Iron Sucrose","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Renibus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Renibus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Renibus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Iron Sucrose","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Renibus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Renibus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Renibus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Series A Financing","leadProduct":"Iron Sucrose","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Renibus Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0.040000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Renibus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Renibus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Iron Sucrose","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Renibus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Renibus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Renibus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Vifor Fresenius Medical Care Renal Pharma","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Iron Sucrose","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Vifor Fresenius Medical Care Renal Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Vifor Fresenius Medical Care Renal Pharma \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"12","companyTruncated":"Vifor Fresenius Medical Care Renal Pharma \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Iron Sucrose","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Renibus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Renibus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Renibus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Iron Sucrose","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Renibus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Renibus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Renibus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2023","type":"Series B Financing","leadProduct":"Iron Sucrose","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Renibus Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"Renibus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Renibus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Juniper Point","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Series B Financing","leadProduct":"Iron Sucrose","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Renibus Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0.070000000000000007,"dosageForm":"Infusion","sponsorNew":"Renibus Therapeutics \/ Juniper Point","highestDevelopmentStatusID":"8","companyTruncated":"Renibus Therapeutics \/ Juniper Point"},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Iron Sucrose","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Renibus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Renibus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Renibus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Iron Sucrose","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Renibus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Renibus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Renibus Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Iron Sucrose

    Menu

    Iron Sucrose

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Renibus Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Renibus Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Stannic Protoporfin,Iron Sucrose

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Renibus Announces Publication Of Results from Phase 2 Study Evaluating RBT-1

                            Details : RBT-1 (stannic protoporfin/iron sucrose), is a potent inducer of anti-inflammatory, antioxidant and iron-scavenging pathways, reduces post-op complications following cardiothoracic surgery.

                            Brand Name : RBT-1

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 09, 2024

                            Lead Product(s) : Stannic Protoporfin,Iron Sucrose

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Renibus Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Renibus Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Stannic Protoporfin,Iron Sucrose

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Renibus Announces First Patient Enrolled in PROTECT Phase 3 Study of RBT-1 to Reduce Post-operative Complicati...

                            Details : RBT-1 (stannic protoporfin/iron sucrose) is a potent inducer of anti-inflammatory, antioxidant and iron-scavenging pathways currently in Phase 3 [NCT # 06021457] for its lead indication to reduce post-operative complications following cardiothoracic surg...

                            Brand Name : RBT-1

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 25, 2023

                            Lead Product(s) : Stannic Protoporfin,Iron Sucrose

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Renibus Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Renibus Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Iron Sucrose,Stannus Protoporphyrin

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Juniper Point

                            Deal Size : $72.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Renibus Therapeutics Announces Final Close of Upsized Series B Financing, Bringing Total Round to $72 Million

                            Details : The proceeds will advance RBT-1 through a pivotal Phase 3 trial for reducing the risk of post-operative complications following cardiothoracic surgery. RBT-1 (stannic protoporfin/iron sucrose) is a potent inducer of anti-inflammatory, antioxidant and iro...

                            Brand Name : RBT-1

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 12, 2023

                            Lead Product(s) : Iron Sucrose,Stannus Protoporphyrin

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Juniper Point

                            Deal Size : $72.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Renibus Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Renibus Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Stannic Protoporfin,Iron Sucrose

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : $47.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Renibus Therapeutics Announces $47 Million Financing to Advance Lead Program RBT-1 Through Pivotal Phase 3 Tri...

                            Details : The proceeds will advance RBT-1 (stannic protoporfin/iron sucrose), a potent inducer of anti-inflammatory, antioxidant and iron scavenging pathways, through Phase 3 trial for reducing the risk of post-operative complications following cardiothoracic surg...

                            Brand Name : RBT-1

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 18, 2023

                            Lead Product(s) : Stannic Protoporfin,Iron Sucrose

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : $47.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Renibus Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Renibus Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Iron Sucrose,Stannus Protoporphyrin

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Renibus Therapeutics Announces Breakthrough Therapy Designation from US FDA for RBT-1 for the Reduction in Ris...

                            Details : RBT-1 (stannic protoporfin/iron sucrose) is a potent inducer of anti-inflammatory, antioxidant and iron-scavenging pathways that is advancing toward for its lead indication to reduce post-operative complications following cardiothoracic surgery.

                            Brand Name : RBT-1

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 11, 2023

                            Lead Product(s) : Iron Sucrose,Stannus Protoporphyrin

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Renibus Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Renibus Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Iron Sucrose,Stannus Protoporphyrin

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Renibus Therapeutics Announces Positive 30-Day Topline Data from RBT-1 Phase 2 Trial

                            Details : RBT-1 (Iron sucrose), treated patients demonstrated a highly significant increase in anti-inflammatory and antioxidant biomarkers of cytoprotective preconditioning. The biomarkers assessed were interleukin-10, heme oxygenase-1 and ferritin.

                            Brand Name : RBT-1

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 05, 2023

                            Lead Product(s) : Iron Sucrose,Stannus Protoporphyrin

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Vifor Fresenius Medical Care Renal Pharma

                            Country arrow
                            Fi Europe 2024
                            Not Confirmed

                            Vifor Fresenius Medical Care Renal Pharma

                            Country arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Iron Sucrose

                            Therapeutic Area : Nephrology

                            Study Phase : Approved

                            Sponsor : Teva Pharmaceutical Industries

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            VFMCRP Announces U.S. Court Upholds Validity of Velphoro® Patent

                            Details : Velphoro (sucroferric oxyhydroxide) ® is a non-calcium, iron-based, chewable phosphate binder approved for the control of phosphate levels in the blood of adults with chronic kidney disease on dialysis.

                            Brand Name : Velphoro

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 22, 2022

                            Lead Product(s) : Iron Sucrose

                            Therapeutic Area : Nephrology

                            Highest Development Status : Approved

                            Sponsor : Teva Pharmaceutical Industries

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Renibus Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Renibus Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Iron Sucrose,Stannus Protoporphyrin

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Renibus Therapeutics Announces Positive Interim Data from RBT-1 Phase 2 Trial

                            Details : RBT-1 (Iron Sucrose) met primary endpoint of increasing the expression of biomarkers of cytoprotective preconditioning; positive data supports the potential for RBT-1 to impact clinical outcomes in cardiothoracic surgery patients.

                            Brand Name : RBT-1

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 15, 2022

                            Lead Product(s) : Iron Sucrose,Stannus Protoporphyrin

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Renibus Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Renibus Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Iron Sucrose,Stannus Protoporphyrin

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : $35.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Renibus Therapeutics Announces Appointment of Frank Stonebanks as CEO and $35 Million Series A Funding

                            Details : Proceeds from the recent financing will be used to advance Renibus’ pipeline, including the company’s lead candidates, RBT-1 for prevention of acute kidney injury (AKI), currently in a large (126 patients), randomized, double-blind study in AKI in a ...

                            Brand Name : RBT-1

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 15, 2022

                            Lead Product(s) : Iron Sucrose,Stannus Protoporphyrin

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : $35.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Renibus Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Renibus Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Iron Sucrose,Stannus Protoporphyrin

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Renibus Therapeutics Initiates Phase 2 Study of RBT-1 for Prevention of Acute Kidney Injury

                            Details : This Phase 2 study will evaluate the efficacy of RBT-1 in generating a preconditioning response as measured by a composite of biomarkers in subjects who are at risk for AKI following cardiac surgery.

                            Brand Name : RBT-1

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 11, 2021

                            Lead Product(s) : Iron Sucrose,Stannus Protoporphyrin

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth